MedTrace Logo

Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

NCT05696977 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2023-12-11

No results posted yet for this study

Summary

This study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

Conditions

  • Nephrotic Syndrome

Interventions

DRUG

Cyclosporine Capsule

Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-17
Primary Completion
2024-02-29
Completion
2024-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05696977 on ClinicalTrials.gov